Category: Intellectual property
-
Patent Awarded for Detailed Pandemic Flu Detection Test
8 October 2014. A genomics-based test to detect various types of pandemic influenza, including mutated forms resistant to antiviral drugs, is the recipient of a recent patent. The U.S. Patent and Trademark Office awarded patent number 8,808,993 — Methods and Kits to Detect New H1N1 “Swine Flu” Variants — to three inventors, and assigned it…
-
Company Launched for Tissue Regrowth, Inflammation Drugs
7 October 2014. Novare Pharmaceuticals, an enterprise commercializing research on a protein that can treat inflammatory diseases and help create new cells for rebuilding tissue, such as after a mastectomy, began operations today under the auspices of Allied Minds, a company creating start-ups based on scientific discoveries at U.S. universities and national labs. The new…
-
Tissue Engineers, Biotech Firm Partner on Cartilage Repair
3 October 2014. Histogenics Corp. that develops replacement cartilage is licensing technology from Intrexon Corp., a biotechnology company producing engineered genetics for commercial applications, for a new process to repair cartilage injuries with a patient’s own cells. The deal has a potential value of at least $44.5 million to Intrexon, but could also result in…
-
Biotech Company Licenses Caltech Immunotherapy Research
24 September 2014. ImmunoCellular Therapeutics Ltd., a developer of cancer therapies harnessing the immune system, is licensing technology developed in the lab of David Baltimore at California Institute of Technology in Pasadena that derives cancer-fighting cells from a person’s own blood-forming stem cells. Financial terms of the exclusive license to ImmunoCellular Therapeutics, based in Los…
-
Boehringer Ingelheim Licenses RNA Lung Cancer Immunotherapy
19 September 2014. The pharmaceutical company Boehringer Ingelheim is licensing from biopharmaceutical enterprise CureVac a vaccine based on RNA to generate an immune response for treating lung cancer. The deal has a total potential value to CureVac of €465 million ($US 597 million). CureVac, in Tübingen, Germany, develops vaccines and treatments based on messenger RNA,…
-
Sanofi, MyoKardia Partner on Genetic Heart Disorders
17 September 2014. The pharmaceutical company Sanofi and biopharmaceutical developer MyoKardia are collaborating on development and commercialization of three MyoKardia therapies for inherited heart diseases. The deal could earn MyoKardia as much as $200 million in milestone payments and equity investments from Sanofi. MyoKardia, in South San Francisco, California, designs small-molecule therapies for two types…
-
Lilly, AstraZeneca Collaborate on Alzheimer’s Drug
16 September 2014. The pharmaceutical companies Eli Lilly and Company and AstraZeneca will jointly develop a drug to treat Alzheimer’s disease, currently in early-stage clinical trials. In the $500 million deal, Lilly is licensing research and development conducted so far by AstraZeneca, with the companies dividing up further clinical development, commercialization, and manufacturing of the…
-
Calico Licenses Neurodegenerative Disease Compounds
11 September 2014. California Life Company, better known as Calico, is licensing for development compounds shown to protect nerve cells in lab animals against degeneration and injury. Financial terms of the deal between Southwestern Medical Center and 2M Company in Dallas, with Calico, a one-year old company backed by Google, were not disclosed. A paper…
-
Patents, Start-Ups Increase in 2013 at U.S. University Labs
10 September 2014. The numbers of patents filed, licensing income, and start-ups generated by research at U.S. universities last year all increased, according to an annual survey conducted by the Association of University Technology Managers (AUTM), the organization of university staff responsible for research commercialization. The survey covers 202 responding institutions of 299 contacted, or…
-
U.S. Patent Awarded for Freeze-Dried Vaccine Formulation
9 September 2014. The technology making possible production and shipping of vaccines in a stable freeze-dried state received U.S. patent protection. Patent no. 8,808,710 was awarded last month by the U.S. Patent and Trademark Office to four inventors and assigned to University of Colorado. Soligenix Inc. in Princeton, New Jersey licensed the technology from University…